GC Biopharma discloses corporate governance report, maintains shareholder return policy and plans to address certain non-compliance items
FY2025 consolidated revenue 1.99 trillion won, operating profit 69.1 billion won, net loss 29.7 billion won, continuing losses
Established a policy to return at least 20% of separate net income for FY2025-2027, 2025 year-end dividend of 1,500 won per share (0.9% yield)
Board of 7 members (3 inside, 4 outside), audit committee and outside director nomination committee composed entirely of outside directors ensuring independence
Non-compliance: shareholder meeting notice sent only 2 weeks prior (required 4 weeks), no CEO succession plan in place
Cumulative voting to be adopted from September 10, 2026; dividend record date set after shareholders' meeting to enhance predictability
[AI Summary]The disclosure of GC Biopharma's corporate governance report shows overall stable governance, but minor shortcomings such as inadequate meeting notice period and lack of succession plan exist, likely having a neutral impact on shareholder value. However, the mid-term shareholder return policy and planned adoption of cumulative voting are positive factors.